Sign In
Buy TVGN
$9.06
+0.590 (+6.97%)
At Close: Jun 03, 2026
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
03:20pm, Wednesday, 05'th Nov 2025
WARREN, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced a clinical milestone in the evolution of its proprietary Exa
Head-To-Head Analysis: Tevogen Bio (TVGN) and The Competition
02:30am, Wednesday, 05'th Nov 2025
Tevogen Bio (NASDAQ: TVGN - Get Free Report) is one of 618 publicly-traded companies in the "MED - BIOMED/GENE" industry, but how does it contrast to its rivals? We will compare Tevogen Bio to similar
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
02:45pm, Monday, 03'rd Nov 2025
WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
12:35pm, Wednesday, 29'th Oct 2025
WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to un
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
03:50pm, Wednesday, 15'th Oct 2025
WARREN, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued an update regarding growing public interest in its
Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records. Potential future T cell therapies could reliably bind to their target nearly ever
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
08:30am, Tuesday, 23'rd Sep 2025
WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral reser
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans
03:40pm, Friday, 19'th Sep 2025
WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Ser
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
11:59am, Wednesday, 10'th Sep 2025
WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and
WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline p
WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billi
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
03:48pm, Thursday, 04'th Sep 2025
WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company's pipeline p
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
04:15pm, Wednesday, 03'rd Sep 2025
WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individu
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
03:20pm, Wednesday, 27'th Aug 2025
WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity
02:50pm, Tuesday, 26'th Aug 2025
WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder a
